Shots:

• The P-III COV-BARRIER study evaluating Baricitinib (4 mg- qd) + SoC (corticosteroids- antimalarials- antivirals- azithromycin) vs PBO + SoC in 1525 patients hospitalized with COVID-19. The patients treated with baricitinib in addition to SoC includes 79% receiving corticosteroids and 19% receiving remdesivir- with some receiving both
• The trial did not meet 1EPs i.e. showed a 38% reduction in mortality by Day 28- non-invasive mechanical ventilation at baseline (17.5% vs 29.4%)
• Lilly plans to publish the data in a peer-reviewed journal in the coming mos. and share the data with regulatory authorities in the US- EU- and other geographies

  Ref: Incyte | Image: Wikipedia